These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24122724)

  • 1. High morbidity and mortality found for high-risk, non-muscle-invasive bladder cancer.
    Barton MK
    CA Cancer J Clin; 2013; 63(6):371-2. PubMed ID: 24122724
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment and survival in patients with recurrent high-risk non-muscle-invasive bladder cancer.
    Chamie K; Ballon-Landa E; Daskivich TJ; Bassett JC; Lai J; Hanley JM; Konety BR; Litwin MS; Saigal CS;
    Urol Oncol; 2015 Jan; 33(1):20.e9-20.e17. PubMed ID: 25443267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence of high-risk bladder cancer: a population-based analysis.
    Chamie K; Litwin MS; Bassett JC; Daskivich TJ; Lai J; Hanley JM; Konety BR; Saigal CS;
    Cancer; 2013 Sep; 119(17):3219-27. PubMed ID: 23737352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.
    Thomas F; Noon AP; Rubin N; Goepel JR; Catto JW
    Eur Urol; 2013 Jan; 63(1):145-54. PubMed ID: 22985746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer.
    Onozawa M; Miyanaga N; Hinotsu S; Miyazaki J; Oikawa T; Kimura T; Takaoka E; Kawai K; Shimazui T; Sakurai H; Nishiyama H; Akaza H
    Jpn J Clin Oncol; 2012 Sep; 42(9):825-30. PubMed ID: 22782963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-bladder cancer mortality in patients with urothelial cancer of the bladder.
    Scosyrev E; Wu G; Golijanin D; Messing E
    Urol Oncol; 2013 Jul; 31(5):656-63. PubMed ID: 21550827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods.
    Matsumoto K; Kikuchi E; Horiguchi Y; Tanaka N; Miyajima A; Nakagawa K; Nakashima J; Oya M
    Urology; 2010 Jun; 75(6):1385-90. PubMed ID: 20110108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
    Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treated natural history of high risk superficial bladder cancer: 15-year outcome.
    Cookson MS; Herr HW; Zhang ZF; Soloway S; Sogani PC; Fair WR
    J Urol; 1997 Jul; 158(1):62-7. PubMed ID: 9186324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment.
    Rodriguez AR
    Urology; 2010 Jun; 75(6):1390-1; author reply 1391. PubMed ID: 20513498
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic factors for survival in patients with recurrence of muscle invasive bladder cancer after treatment with curative intent.
    Ploeg M; Kums AC; Aben KK; van Lin EN; Smits G; Vergunst H; Viddeleer AC; Geboers AD; van Berkel H; van Boven E; Kiemeney LA; Witjes F
    Clin Genitourin Cancer; 2011 Sep; 9(1):14-21. PubMed ID: 21723794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm?
    Thomas F; Rosario DJ; Rubin N; Goepel JR; Abbod MF; Catto JW
    Cancer; 2012 Nov; 118(22):5525-34. PubMed ID: 22544645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Earlier use of aggressive therapy could prevent one-third of bladder cancer deaths.
    Pinkowish MD
    CA Cancer J Clin; 2009; 59(3):142-4. PubMed ID: 19369683
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer.
    Rink M; Xylinas E; Babjuk M; Hansen J; Pycha A; Comploj E; Lotan Y; Sun M; Karakiewicz PI; Abdennabi J; Fajkovic H; Loidl W; Chun FK; Fisch M; Scherr DS; Shariat SF
    J Urol; 2012 Dec; 188(6):2120-7. PubMed ID: 23083868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection.
    Deng N; Chen JX; Chen LW; Qiu SP; Li XF; Wang DH
    Chin Med J (Engl); 2012 Oct; 125(20):3681-6. PubMed ID: 23075724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.